Fighting Cancer Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

Introducing the OraMark™ Laboratory Developed Test for the U.S!

Learn More about OraMark™
vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • vb-400x210

    Vigilant Biosciences Announces Oral Presentation on Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer at the American Academy of Otolaryngology– Head and Neck Surgery Foundation 2016 Annual Meeting

    FORT LAUDERDALE, Fla. and SAN DIEGO, AAO-HNS Annual Meeting – Sept. 16, 2016 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced an oral presentation of…more

  • vb-400x210

    Vigilant Biosciences Announces Poster Presentation on Measuring CD44 and Total Protein Levels to Predict Head and Neck Squamous Cell Carcinoma at 7th European Conference on Head and Neck Oncology

    FORT LAUDERDALE, Fla. and BUDAPEST, Hungary, Sept. 6, 2016 /PRNewswire/ — ECHNO Conference — Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced a presentation of data…more

  • Nikon-s-Rob-Zibilich-Talks-to-Clinical-Lab-Products-on-the-Evolution-of-the-Clinical-Lab

    Vigilant Biosciences Receives Funds to Develop Oral Cancer Diagnostic

    Vigilant Biosciences Inc, Fort Lauderdale, Fla, has received a Phase I Small Business Innovation Research (SBIR) grant in the amount of $219,454 from the National Institute of Dental and Craniofacial Research (NIDCR). The 15-month grant will fund research by Vigilant…more

  • sunsentinel

    Fort Lauderdale biotech receives small-business research grant

    Fort Lauderdale-based Vigilant Biosciences announced Thursday it has received a Small Business Innovation Research grant for more than $200,000 from the National Institute of Dental and Craniofacial Research. The 15-month grant will finance research to develop a diagnostic test that…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×